BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 36734081)

  • 1. HBsAg (-)/HBsAb (-)/HBeAg (-)/HBeAb (+)/HBcAb (+) predicts a high risk of hepatitis B reactivation in patients with B-cell lymphoma receiving rituximab based immunochemotherapy.
    Shui LP; Zhu Y; Duan XQ; Chen YT; Yang L; Tang XQ; Zhang HB; Xiao Q; Wang L; Liu L; Luo XH
    J Med Virol; 2023 Feb; 95(2):e28549. PubMed ID: 36734081
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reactivation of hepatitis B virus infection following rituximab treatment in HBsAg-negative, HBcAb-positive rheumatoid arthritis patients: A long-term, real-world observation.
    Chen YM; Chen HH; Huang WN; Chen YH; Hsieh TY; Yang SS; Lan JL; Chen DY
    Int J Rheum Dis; 2019 Jun; 22(6):1145-1151. PubMed ID: 31117160
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determining Whether Prophylactic Antiviral Treatment Is Necessary in HBsAg-Negative/HBcAb-Positive Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation.
    Zhang A; Wu Y; Tan Y; Shi J; Zhao Y; Hu Y; Yu J; Zheng W; Lai X; Zhang M; Zhu Y; Ye Y; Huang Y; Fu S; Huang H; Luo Y
    Biol Blood Marrow Transplant; 2020 May; 26(5):956-964. PubMed ID: 31962163
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of hepatitis B reactivation in HBsAg-negative/HBcAb-positive patients with undetectable serum HBV DNA after treatment with rituximab for lymphoma: a meta-analysis.
    Tang Z; Li X; Wu S; Liu Y; Qiao Y; Xu D; Li J
    Hepatol Int; 2017 Sep; 11(5):429-433. PubMed ID: 28856548
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatitis B virus reactivation and hepatitis in diffuse large B-cell lymphoma patients with resolved hepatitis B receiving rituximab-containing chemotherapy: risk factors and survival.
    Chen KL; Chen J; Rao HL; Guo Y; Huang HQ; Zhang L; Shao JY; Lin TY; Jiang WQ; Zou DH; Hu LY; Wirian ML; Cai QQ
    Chin J Cancer; 2015 May; 34(5):225-34. PubMed ID: 26058465
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of the HBV reactivation in isolated HBcAb positive patients affected with Non Hodgkin Lymphoma.
    Masarone M; De Renzo A; La Mura V; Sasso FC; Romano M; Signoriello G; Rosato V; Perna F; Pane F; Persico M
    BMC Gastroenterol; 2014 Feb; 14():31. PubMed ID: 24533834
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low incidence of hepatitis B virus reactivation during chemotherapy among diffuse large B-cell lymphoma patients who are HBsAg-negative/ HBcAb-positive: a multicenter retrospective study.
    Ji D; Cao J; Hong X; Li J; Wang J; Chen F; Wang C; Zou S
    Eur J Haematol; 2010 Sep; 85(3):243-50. PubMed ID: 20491883
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatitis B virus reactivation in B-cell lymphoma patients treated with rituximab: analysis from the Asia Lymphoma Study Group.
    Kim SJ; Hsu C; Song YQ; Tay K; Hong XN; Cao J; Kim JS; Eom HS; Lee JH; Zhu J; Chang KM; Reksodiputro AH; Tan D; Goh YT; Lee J; Intragumtornchai T; Chng WJ; Cheng AL; Lim ST; Suh C; Kwong YL; Kim WS
    Eur J Cancer; 2013 Nov; 49(16):3486-96. PubMed ID: 23910494
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatitis B reactivation in HBsAg-negative/HBcAb-positive patients receiving rituximab for lymphoma: a meta-analysis.
    Mozessohn L; Chan KK; Feld JJ; Hicks LK
    J Viral Hepat; 2015 Oct; 22(10):842-9. PubMed ID: 25765930
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Moderate Risk of Hepatitis B Virus Reactivation in HBsAg
    Kuo MH; Tseng CW; Lee CH; Tung CH; Tseng KC; Lai NS
    Sci Rep; 2020 Feb; 10(1):2456. PubMed ID: 32051458
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of hepatitis B reactivation in HBsAg-/HBcAb+ patients after biologic or JAK inhibitor therapy for rheumatoid arthritis: A meta-analysis.
    Hong X; Xiao Y; Xu L; Liu L; Mo H; Mo H
    Immun Inflamm Dis; 2023 Feb; 11(2):e780. PubMed ID: 36840482
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence of some hepatitis B virus markers among pregnant women attending antenatal clinic in Specialist Hospital Sokoto Nigeria.
    Erhabor O; Mohammad SY; Bello L; Onuigwe FU; Abdulrahman Y; Zama I; Buhari H; Bagudo A; Ibrahim K; Ahmed M; Udomah FP; Adias TC; Erhabor T; Okara GC
    Hum Antibodies; 2020; 28(3):233-243. PubMed ID: 32333583
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatitis B reactivation in HBsAg-negative/HBcAb-positive patients receiving immunosuppressive therapy for glomerulonephritis: a retrospective analysis.
    Fang J; Li W; Peng X; Tan Z; Tan M; Zhang C; Wang W; Xu Z; Zhou G
    Int Urol Nephrol; 2017 Mar; 49(3):475-482. PubMed ID: 28032257
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rituximab increases the risk of hepatitis B virus reactivation in non-Hodgkin lymphoma patients who are hepatitis B surface antigen-positive or have resolved hepatitis B virus infection in a real-world setting: a retrospective study.
    Tsai YF; Yang CI; Du JS; Lin MH; Tang SH; Wang HC; Cho SF; Liu YC; Su YC; Dai CY; Hsiao HH
    PeerJ; 2019; 7():e7481. PubMed ID: 31565551
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Markers of hepatitis B infection in Tari District, Southern Highlands Province, Papua New Guinea.
    Sanders RC; Lewis D; Dyke T; Alpers MP
    P N G Med J; 1992 Sep; 35(3):197-201. PubMed ID: 1296422
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of hepatitis B virus (HBV) reactivation in hepatitis B surface antigen negative/hepatitis B core antibody positive patients receiving rituximab-containing combination chemotherapy without routine antiviral prophylaxis.
    Koo YX; Tay M; Teh YE; Teng D; Tan DS; Tan IB; Tai DW; Quek R; Tao M; Lim ST
    Ann Hematol; 2011 Oct; 90(10):1219-23. PubMed ID: 21520001
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and virological factors associated with hepatitis B virus reactivation in HBsAg-negative and anti-HBc antibodies-positive patients undergoing chemotherapy and/or autologous stem cell transplantation for cancer.
    Borentain P; Colson P; Coso D; Bories E; Charbonnier A; Stoppa AM; Auran T; Loundou A; Motte A; Ressiot E; Norguet E; Chabannon C; Bouabdallah R; Tamalet C; GĂ©rolami R
    J Viral Hepat; 2010 Nov; 17(11):807-15. PubMed ID: 20002298
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence and clinical characteristics of hepatitis B virus reactivation in HBsAg-negative/HBcAb-positive patients receiving rituximab for rheumatoid arthritis.
    Tien YC; Yen HH; Chiu YM
    Clin Exp Rheumatol; 2017; 35(5):831-836. PubMed ID: 28375829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Kidney Transplantation From Hepatitis B Surface Antigen (HBsAg)-Positive Living Donors to HBsAg-Negative Recipients: Clinical Outcomes at a High-Volume Center in China.
    Wang XD; Liu JP; Song TR; Huang ZL; Fan Y; Shi YY; Chen LY; Lv YH; Xu ZL; Li XH; Wang L; Lin T
    Clin Infect Dis; 2021 Mar; 72(6):1016-1023. PubMed ID: 32100025
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High prevalence of past hepatitis B virus infection in diffuse large B cell lymphoma: a retrospective study from Italy.
    Visentini M; Pica A; D'Ippolito G; Sculco E; La Gualana F; Gragnani L; Miglionico M; Mazzaro C; Fiorilli M; Basili S; Martelli M; Di Rocco A; Casato M; Gentile G; Pulsoni A
    Ann Hematol; 2023 Dec; 102(12):3457-3463. PubMed ID: 37650886
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.